Medicinal Chemistry Consultant Specializing in Drug Discovery, Process Research and Development, Organic Synthesis, cGMP, Chemical Hygiene and Lab Safety, EPA, OSHA Compliance

Technical Consultant #1746

Medicinal chemistry, process research and development, and organic synthesis.
Drug discovery, including small molecule structure-based design and SAR optimization in collaboration with CADD, biology, ADMET, and informatics teams.
Design and synthesis of complex organic compounds for medicinal applications.
Rational, structure-based drug design and development.
Design and execution of optimized, scalable, safe chemical processes for drug intermediates and APIs at multi-kilogram scales.
Synthesis of substituted aromatics, aliphatics, heterocycles, fluorinated analogs, oligopeptides, cyclic peptides, peptidomimetics, organosilanes, organometallics, chiral compounds and inorganics.
cGMP synthesis and FDA documentation.
Kinase inhibitors.
PARP inhibitors.
Cysteine protease inhibitors.
Angiotensin receptor antagonists.
Glycoprotein IIb/IIIa (GP2b3a) receptor antagonists.
NSAIDs.
IP due diligence.
Chemical Hygiene and Laboratory Safety; EPA, OSHA compliance.
Hands-on expertise with the latest computer-integrated analytical and preparative instrumentation, including multi-probe high-field NMR, FT-IR, LC-MS, HPLC, MPLC (ISCO), and RP-HPLC (Gilson).

Undisclosed Company, Senior Scientist, 1994 - 2010

Drug Discovery Group Leader, Medicinal Chemistry Department.
Supervised technical and professional staff within multi-disciplinary teams.
Discovered and developed novel, patented kinase inhibitors (ALK, cMet, JAK).
Discovered and developed novel, patented PARP-1 inhibitors; co-inventor of CEP-9722, in clinical trials for adjuvant cancer therapy.
Invented and developed 1,2-Benzothiazine-1,1-dioxides, a patented NCE for Calpain-1 inhibitors as potential stroke therapy.
Invented novel, patented Calpain-1 peptidomimetic inhibitors.
Chemical Hygiene Manager, Laboratory Safety, EPA and OSHA compliance.

E. I. DuPont de Nemours & Co. Wilmington, DE, 1984 - 1994

As Scientist and Senior Scientist at DuPont-Merck Pharmaceutical Co., Experimental Station Laboratory;
Co-invented Losartan (Cozaar®), a blockbuster first-in-class all receptor antagonist for treatment of hypertension.
Co-developed an optimized synthetic process for Losartan; co-managed synthesis of pre-clinical supplies.
Discovered and developed cyclic peptides as glycoprotein IIb/IIIa (GP2b3a) receptor antagonists for potential antiplatelet medication.
Process Research and Development Group Leader and Supervisor.
Designed and optimized chemical process for NSAID clinical candidate, DuP-697.
Delivered multi-kilogram cGMP and non-GMP supplies of various APIs and intermediates under deadline and budget for several pre-clinical and clinical candidates.
Consulted vendor CRO for related activities.

Merck, Sharpe and Dohme & Co., Rahway, NJ, Research Chemist, 1979 - 1980

Angiotensin Converting Enzyme (ACE) inhibitors; synthesized peptidomimetics and contributed to SAR activities helping lead to Enalapril®, a blockbuster drug for treatment of hypertension.

Academic and Professional Affiliations

American Chemical Society - Medicinal Chemistry Division, Organic Chemistry Division

Publications and Patents